

**Amendment to the Claims:**

Please amend the claims to read as follows:

1-20. (canceled)

21. (currently amended) An arabinogalactan protein composition, having a weight average molecular weight of at least 100 kiloDaltons, and comprising about 5% protein, said protein having an amino acid content of about 20% hydroxyproline, isolated from a purified arabinogalactan composition isolated from *Astragalus membranaceus* plants.

22. (currently amended) The arabinogalactan protein composition of claim 21 where the purified arabinogalactan protein composition is isolated from the roots of *Astragalus membranaceus* plants.

23. (previously presented) The arabinogalactan protein composition of claim 21 where the *Astragalus membranaceus* plants are plants of *A. membranaceus* Bge. var. *mongholicus* (Bge.) Hsiao or *A. membranaceus* (Fisch.) Bge.

24. (previously presented) The arabinogalactan protein composition of claim 21 that is isolated from *Astragalus membranaceus* plants grown in Inner Mongolia or Shanxi province, Peoples' Republic of China.

25. (previously presented) The arabinogalactan protein composition of claim 21 where the *Astragalus membranaceus* plants are two-year old *Astragalus membranaceus* plants.

26. (previously presented) The arabinogalactan protein composition of claim 21 having an arabinose/galactose ratio of at least 2.

27. (previously presented) The arabinogalactan protein composition of claim 21 having an endotoxin content of not more than 1.0 EU/mg.

28. (currently amended) An aqueous intravenously injectable arabinogalactan protein formulation comprising:

- (a) a therapeutically effective amount of the arabinogalactan protein composition of claim 21; and
- (b) an aqueous intravenously injectable excipient.

29-38. (canceled)